AstraZeneca PLC Doubles Down On Diabetes With $4.1bn Buyout

Shares in AstraZeneca PLC (LON:AZN) hit an 11-year high as investors applaud the deal.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Giant pharmaceutical companies have had a tricky few years. As the blockbuster drugs that fuelled their meteoric rise have lost patent protection, they have become vulnerable to competition from generic manufacturers who can turn out unbranded pills more cheaply.

For a company like AstraZeneca (LSE: AZN) (NYSE: AZN.US), that’s raised questions about how it will shore up its sliding sales. Turnover has already fallen from nearly £22bn in 2008 to £17bn last year.

One option is to hope that new wonder pills can pop off the production pipeline, and indeed that’s what’s happened over at GlaxoSmithKline. However, AstraZeneca is judged by many analysts to be some way behind its arch-rival at getting over the so-called ‘patent cliff’, which could mean a few more lean years for revenues and profits unless something else is done.

So another appealing option for the pharmaceutical giants has been to deploy their financial reserves to buy-in or bulk up in promising areas for growth.

And that’s just what AstraZeneca has done, striking a deal with US company Bristol-Myers Squibb to acquire ownership of the pair’s diabetes treatment joint venture.

A $4bn bet

AstraZeneca could pay up to $4.1bn for the 50% of the joint venture it doesn’t already own. A cool $2.7bn will be payable on completion of the deal, and a further $1.4bn is likely to be forked out as various milestones and targets are hit.

The joint venture didn’t last long. The collaboration began in 2007, but it only really achieved scale in summer 2012, when AstraZeneca and Bristol-Myers teamed up to acquire Amylin Pharmaceuticals for around $7 billion. Among other things, Amylin had developed an appealing new drug that reduced the number of daily injections that diabetes patients required from two to one.

The firms paid roughly $3.4 billion each for a 50% share in what was hailed by some industry observers as an innovative joint venture, but sales and the progress of other drugs in development have disappointed.

What’s the deal with diabetes?

Why, then, would AstraZeneca want to double down on diabetes?

Well, for starters it’s a growing menace. Already some 350m people suffer from the condition, but the number is forecast to grow to over 550m by 2030. Around two-thirds of these patients live in emerging markets, which gives the drugs company an especially attractive demographic to tap into.

That’s the long-term story; in the short term, AstraZeneca will try to be more nimble and efficient in exploiting the diabetes treatments the venture has developed. This isn’t an idle hope. The pharmaceutical giants achieved their enormous size – AstraZeneca is a £45bn company, remember – precisely because it’s a business where economies of scale matter.

In addition, Bristol-Myers Squibb wanted out, as it seeks to focus on other diseases such as cancer. Hence the price was probably right for the UK behemoth.

Dividend safe, says AstraZeneca

Of course, $4.1bn is a lot of money even for a huge company like AstraZeneca. The firm has a strong balance sheet, however, and says it can finance the deal from its existing spare cash and credit facilities.

Net debt will increase, but given the company’s mighty cashflow that won’t be a worry for now. The company says it will maintain its progressive dividend policy, and claims the deal – which should complete in January – will be neutral for earnings expectations in 2014.

With the shares on an attractive dividend yield of around 5% and looking fairly good value with a P/E ratio of 12, it is little wonder AstraZeneca’s share price rose on the news. However, the real test of whether treating diabetes can help the company staunch its haemorrhaging revenues will take many years to play out.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

> Owain owns shares in AstraZeneca. The Motley Fool has recommended shares in AstraZeneca.

More on Company Comment

Hand of person putting wood cube block with word VALUE on wooden table
Company Comment

Value has been building behind the Diageo share price

Despite the business growing, the Diageo share price first reached its current level just over 19 months ago and hasn't…

Read more »

Older couple walking in park
Investing Articles

5 stocks to buy for high and rising dividend income

I can see a host of shares to buy on the FTSE 100 offering me exceptional levels of income. Here…

Read more »

Young mixed-race woman looking out of the window with a look of consternation on her face
Investing Articles

I don’t care if FTSE 100 shares fall further, I’m buying them today

I'm happy to go shopping for FTSE 100 shares today, even though I accept that they could have further to…

Read more »

Happy young female stock-picker in a cafe
Investing Articles

Rolls-Royce shares are down 18% in a month and I’m finally going to buy them

Investors who bought Rolls-Royce shares have been repeatedly disappointed, but I'm willing to take a chance on them before they…

Read more »

Storytelling image of a multiethnic senior couple in love - Elderly married couple dating outdoors, love emotions and feelings
Investing Articles

How I’d invest £10k in a Stocks and Shares ISA today

Now looks like a good time to buy cheap FTSE 100 shares inside a Stocks and Shares ISA. These are…

Read more »

Black father holding daughter in a field of cows
Investing Articles

Today’s financial crisis is the perfect moment to buy cheap shares

I'm building a portfolio of FTSE 100 stocks by purchasing cheap shares whenever I see an opportunity. There's a good…

Read more »

Long-term vs short-term investing concept on a staircase
Investing Articles

I’d buy Tesco shares in October to bag their 5.4% yield 

Tesco shares have fallen lately but I think this makes them attractively valued for a dividend stock I would aim…

Read more »

Young mixed-race woman looking out of the window with a look of consternation on her face
Investing Articles

I would do anything to hold Diageo in my portfolio (but I won’t do that)

Diageo is one of my favourite stocks on the entire FTSE 100 and I'd love to hold it, but one…

Read more »